- Messages
- 664
- Reaction score
- 1
- Points
- 0
This study showed some promising results in using a type of glucose treat seizures. I wrote to DogtorJ and asked him to comment on the science of it and how this might be done with diet.
It's a good read.
"Experimental Agent Shows Promise as Safe, Effective Antiepileptic
Medscape Medical News 2006. © 2006 Medscape
Caroline Cassels
December 7 2006 (San Diego) — An experimental agent is showing promise as an effective and safe replacement for the ketogenic diet and may pave the way for a new class of drugs to treat temporal lobe epilepsy (TLE), a new study suggests.
Presented here at the First North American Regional Epilepsy Congress and published in the November 2006 issue of Nature Neuroscience (Garriga-Canut M et al. Nat Neurosci. 2006;9:1382-1387), researchers at the University of Wisconsin, in Madison, found the glycolytic inhibitor 2-deoxy-D-glucose (2DG) has anticonvulsant and antiepileptic properties in rodent models of epilepsy.
Although still in the experimental stages, the study's principal investigator, Avtar Roopra, PhD, told Medscape the study's findings are "very exciting" and may represent a breakthrough in TLE, which is commonly drug resistant."
Link to full article:
http://www.medscape.com/viewarticle/548977_print
It's a good read.
"Experimental Agent Shows Promise as Safe, Effective Antiepileptic
Medscape Medical News 2006. © 2006 Medscape
Caroline Cassels
December 7 2006 (San Diego) — An experimental agent is showing promise as an effective and safe replacement for the ketogenic diet and may pave the way for a new class of drugs to treat temporal lobe epilepsy (TLE), a new study suggests.
Presented here at the First North American Regional Epilepsy Congress and published in the November 2006 issue of Nature Neuroscience (Garriga-Canut M et al. Nat Neurosci. 2006;9:1382-1387), researchers at the University of Wisconsin, in Madison, found the glycolytic inhibitor 2-deoxy-D-glucose (2DG) has anticonvulsant and antiepileptic properties in rodent models of epilepsy.
Although still in the experimental stages, the study's principal investigator, Avtar Roopra, PhD, told Medscape the study's findings are "very exciting" and may represent a breakthrough in TLE, which is commonly drug resistant."
Link to full article:
http://www.medscape.com/viewarticle/548977_print